An analysis of the vaginal microbiota in women positive for group B Streptococcus during the third trimester of pregnancyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared the vaginal microbiota of pregnant women who tested positive versus negative for Group B Streptococcus (GBS) colonization in the third trimester. GBS colonizes 20 to 40 percent of pregnant women and is linked to preterm birth and neonatal infection.
How was it studied?
This retrospective case-control study enrolled 53 women at 35 to 37 weeks of gestation from Shenyang Women and Infants Hospital, 22 GBS culture-positive and 31 GBS culture-negative. Reproductive tract swabs underwent 16S rRNA sequencing on the Illumina NovaSeq platform, alongside chi-square and logistic regression analysis of clinical risk factors.
What did they find?
Premature rupture of membranes, preterm delivery, diabetes mellitus, poor vaginal cleanliness, elevated vaginal leukocytes, and fungal colonization were all associated with GBS colonization. The GBS-positive group had greater species richness, lower community evenness, and a notable drop in Lactobacillus abundance, alongside a higher relative proportion of Gardnerella. Beta diversity differed significantly between the two groups.
Why it matters
The findings suggest GBS colonization is entangled with broader vaginal dysbiosis, not an isolated event, pointing toward microbiota-targeted strategies to reduce GBS-related pregnancy and neonatal complications.